Results
|
|
1.
|
Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41. MedStar authors:
Year: 2023
Citation: - Breast Cancer Research & Treatment. 199(2):243-252, 2023 Jun.
Department:
- Associate Dean for Research Development
- MedStar Health
Medline publication type:
- Journal Article
- Randomized Controlled Trial
All authors: - Azar CA, Baez-Diaz L, Bandos H, Bear HD, Boileau JF, Brufsky AM, Geyer CE Jr Hassan S, Magrinat GC, Mamounas EP, Paik S, Rastogi P, Sarwar S, Shibata HR, Suga JM, Swain SM, Tang G, Wolmark N, Yothers G
|
|
|
2.
|
|
|
|
3.
|
Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study. MedStar authors:
Year: 2022
Citation: - Journal of Clinical Oncology. 40(5):438-448, 2022 02 10.
Department: - Associate Dean for Research Development
Medline publication type:
All authors: - Barrios C, Bonnefoi H, Boulet T, De Laurentiis M, Ellis PA, Fehrenbacher L, Gianni L, Gralow J, Harbeck N, Huang CS, Im SA, Im YH, Ito Y, Krop IE, Liu H, Macharia H, Nowecki Z, Shah J, Song C, Swain SM, Toi M, Trask P, Winer EP
|
